Kevin Brindle is Professor of Biomedical Magnetic Resonance at Cancer Research UK’s Cambridge Research Institute. His early work studied enzyme kinetics in cells and tissues using molecular genetics, isotope exchange and magnetization transfer. More recently his aim has been to develop imaging methods that give an early indication of tumour treatment response. His studies led to MRI being used in a Phase I trial of a new anti-vascular drug to obtain an earlier indication of efficacy and he developed an MRI contrast agent for detecting tumour cell death in vivo. Since 2006 he has been developing, in collaboration with GE Healthcare, a technique that increases NMR sensitivity by over 10,000 fold.